2024 Patients Pharma Pharmaceutical manufacturing 
Medico Reach
FEBRUARY 8, 2023
The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. The global pharmaceutical manufacturing market stood at USD 405.52 billion during 2020-2024. Are you intrigued to know what technologies will rule the pharma market and how they can benefit your business in 2023?
PM360
NOVEMBER 14, 2023
This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap OOP costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024. The price is available to cash-paying patients with a valid prescription. for only $35. Currently, an estimated 37.3 of the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 16, 2022
The negotiations over the treaty are being hosted through the World Health Organization (WHO), with plans to officially adopt a binding agreement sealed by the United Nations health agency’s member countries in May 2024. The discussions over the treaty are set to continue for some time.
European Pharmaceutical Review
JULY 21, 2023
Recent guidance published by the European Medicines Agency outlines measures that will be taken to increase preparedness for the autumn/winter 2023-2024. Recommendations were also published earlier this year for all stakeholders in the pharma supply chain.
pharmaphorum
NOVEMBER 25, 2022
The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting.
European Pharmaceutical Review
DECEMBER 18, 2023
For example, due to prevalence of the disease across the globe, US approval of the biologic lecanemab was particularly anticipated by both the industry and patients. The findings were published in the NEMJ in April 2023 and demonstrated “the best solid tumour CAR-T data reported to date – and by a country mile!
PM360
MAY 21, 2024
Manufacturer assistance programs are designed to make treatments more affordable, yet only about 10% of these dollars are used by patients. The cost of filling a prescription can keep 21% of patients from getting an Rx, and one in ten patients will modify their treatment plan because of cost, according to recent polling data from KFF.
Expert insights. Personalized for you.
52 
Let's personalize your content